Acadia Pharmaceuticals Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing

NEW YORK, March 16, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for Acadia Pharmaceuticals Inc. shareholders (NASDAQ:ACAD). Concerned ACAD investors who purchased between January 13, 2015 and March 11, 2015 are encouraged to contact securities attorney Hamilton Lindley by clicking here.

The law firm's investigation will focus on potential violations of securities law by Acadia Pharmaceuticals Inc. Acadia announced on March 11, 2015 that it would be delaying submission of a New Drug Application for its drug Nuplazid. Acadia also announced that Uli Hacksell, its CEO, is retiring. Acadia shares were down more than 20% on intraday trading the following day. Our potential shareholder lawsuit will seek to ensure that Acadia Pharmaceuticals Inc. works to enrich shareholders, not just the management.

Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. ACAD stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/ACAD.

Find these Waco personal injury attorneys, trucking accident attorneys and car wreck attorneys on Google+, Facebook, Twitter and LinkedIn.

SOURCE Dunnam & Dunnam

Related Links

http://www.dunnamlaw.com